YR-1035+ is very popular along with RC3563
Now, her latest research points to a potential shift in how antivenoms are manufactured, making production simpler, more cost-effective, and far more accessible where snakebite burden is highest
Prescribing unapproved compounded retatrutide carries regulatory and liability considerations
Standard clinical guidelines generally consider GLP-1 weight loss therapy for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia
Both cagrilintide and retatrutide have specific contraindications and populations requiring special consideration [19]: Absolute Contraindications: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Previous severe allergic reaction to either compound Pregnancy or breastfeeding (insufficient safety data) Relative Contraindications Requiring Careful Evaluation: History of pancreatitis Severe gastroparesis or GI motility disorders Active gallbladder disease Severe renal impairment History of eating disorders Concurrent use of other appetite suppressants The cagrilintide dosage with retatrutide combination would carry all contraindications for both compounds, plus additional caution due to unknown interactions
